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Hyaluronic acid is an unbranched high molecular weight
polysaccharide, consisting of repeating disaccharide units of
glucuronate- 1, 3N acetyl glucosamine linked by 1-4 bonds.
The introduction of sensitive assays has now made it
possible to detect HA in very low concentrations (Engstrom-
Laurent et al., 1985a; Delpech et al., 1985). Tissue HA enters
the circulation via the lymph and is rapidly extracted and
catabolised by the liver (Laurent & Fraser, 1986), resulting
in a normal serum HA level of 10-lOO1 gl-1. The level of
HA can rise in cirrhosis (Engstrom-Laurent et al., 1985b)
and rheumatoid arthritis (Engstrom-Laurent & Hillgren,
1985) and in end stage renal failure (Hallgren et al., 1987).
There have been a few reports of raised serum levels of
HA in advanced cancer; Delpech et al. (1985) made this
observation when developing their enzymoimmunologic
assay. Later they used this test to investigate the HA
concentrations in the serum and pleural effusions in meso-
thelioma and observed high levels in advanced disease (mean
750pgl-1; range 29-5,833Mgl-1), but the test was unsuitable
for early diagnosis (Frebourg et al., 1987). Manley & Warren
(1987) using a nephelometric assay also observed raised
serum HA levels in cancer, but their technique gave much
higher concentrations for normal HA levels (mean
l.O9mgl-1; range 0-4mgl-1).
The availability of a commercial radiometric (HA test 50,
Pharmacia, Uppsala, Sweden) has provided an opportunity
to extend these preliminary observations. This assay has
been developed from the method described by Tengblad
(1980) and Laurent & Tengblad (1980).
The test is based on the use of specific hyaluronic acid
binding proteins, (HABP) isolated from bovine cartilage.
First the hyaluronic acid from the sample is allowed to bind
1251-labelled HABP in solution for at least 60min. The
unbound 125J- HABP is then quantitated by incubating with
HA covalently coupled to sepharose particles of small size
and low density. The particles stay suspended during the
45 min incubation. Separation is performed by centrifugation
followed by decanting. The radioactivity bound to the
particles is measured. It is inversely proportional to the
concentration of HA in the sample. The assay has a
detection limit of <5,pgl-, and an operating range of <5-
500pgl-1. The coefficient of variation within and between
assays was 6.5 and 4.9% respectively for a sample with a
mean value of 29.Opgl- , 5.2 and 8.0% respectively for a
sample with a mean value of 312pugl-1. The assay measures
HA with a wide range of relative molecular weights ranging
from < 106 - 5 x 103 kD. The manufacturer's data indicate
that there is a marked age dependency for the normal values
rising from a mean of 18-69 pgI1 as age rose from <20-
>60 years old. We chose our controls from healthy persons
between 42 and 64 years, median 54 years.
The distribution of serum HA values in the controls and
121 adult patients with metastatic cancer or large local
tumours at presentation is shown in Figure 1. It is evident
that within each type of cancer individual patients can show
strongly elevated levels of HA, but statistical significance
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Figure I Distribution of serum HA levels in advanced cancer.
(Spearman rank test) for an overall increased level compared
to the controls was only present in pancreatic cancer
(P=0.0097), small cell lung cancer (P=0.01) and carcinoma
of the prostate (P=0.0069). Sera from 20 patients with
hepatic metastases gave a median HA of 74pg1 1 and range,
21-970pg1 1; and sera from 20 patients with metastases
involving bone had a median HA of 66.5pgl-1 and range,
3-789pugl-1; both were not significantly different to normal
by a non-parametric analysis.
Whilst the patients with raised HA (>130ng11) tended
to have other tumour markers that were raised, there were
other patients with normal HA levels and raised marker
levels, e.g., in carcinoma of the pancreas HA vs. CEA
(>5ngml-1) 9:12, in colorectal 2:6, in prostate cancer HA
vs. PSA (>lOngml-1) 7:11 in small cell lung cancer HA vs.
NSE (>13ngml-1) 8:18. The induction of clinical and
biochemical remission in metastatic prostatic cancer by hor-
mone manipulation was not associated with any significant
change in HA level as shown by a paired t-test for 9 paired
values (P=0.2865).
The levels of serum HA are age dependent; in persons
<20 years the 95th percentile is 37ypgl-. When sera from
patients with untreated Wilms' tumour or neuroblastoma
were measured it was evident that Wilms' tumour patients
had a high incidence of greatly raised HA levels; in over a
third the levels were >500pg1-1, and in 4 of them
>20,000pgI-1. In neuroblastoma, by contrast, the pattern
was similar to that seen in adult cancers with a median level
of 25pugl-1 and range, 11-327pgl-1 (Table 1). The raised
levels of HA in Wilms' tumour did not appear to be stage
dependent, levels > 500pg1 1 occurring in some patients
with all stages. The molecular weight distribution of HA in
the sera of 2 patients with Wilms' tumours was analysed by
high performance gel chromatography (Superose 6, Pharma-
cia). Both samples showed that the predominant form of HA
was a high molecular weight polymer (>106kD) and this
was associated with a wide range of smaller polymers to ~104kD (Figure 2).
These studies confirm that a raised serum HA may
accompany malignant disease but cannot be considered as a
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Table I Serum HA levels in Wilms' tumour and neuroblastoma
Distribution of serum HA (pgi-)
Disease Stage n < 100 100-500 501-5,000 >5,000
Wilms' tumour I and II 19 8 5 5 1
III and IV 13 3 3 3 4
Neuroblastoma III and IV 18 15 3 0 0
15000 A 440K 25K
10 000 -
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0
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Figure 2 Distribution of immunoreactive HA in serum from a
patient with Wilms' tumour (serum HA >20,000ng1- l) fraction-
ated on a Superose 6 gel filtration column. (200,l serum
applied, flow rate 0.5mlmin-1): indicating the majority of the
HA is in the exclusion volume (exclusion limit > 106 D), markers
at 440 and 25kD.
tumour marker. The results suggest that this phenomenon is
particular to individual patients and generalisations cannot
be made about the effects of the metastatic involvement of a
particular tissue, as shown by the lack of elevation of the
median levels in cancers with skeletal metastases and myelo-
matosis, or in patients with hepatic metastases. HA is
normally cleared very rapidly from the circulation, mostly by
the liver with a minor fraction of lower molecular weight
polymer metabolised by the kidney (Hallgren et al., 1987).
Whilst cirrhosis is associated with a raised serum HA,
metastatic cancer involving the liver rarely produces severely
reduced liver function. Nevertheless, a rise can be observed
in individual patients with time, and probably comes from
the overproduction of HA by certain tumours.
As yet, the mechanism of increased serum levels of HA in
cancer is unclear. However, there are some clues from the
case reports. Greatly increased levels of serum HA have been
observed in Wilms' tumour (Powars et al., 1972; Wu et al.,
1984; Ater et al., 1984; Bracey et al., 1987) and neuro-
blastoma (Broughton et al., 1970). In a few patients the rise
of serum HA was associated with increased viscosity. These
reports were based on relatively insensitive chemical assays
but pointed out that certain tumours have a great propensity
for HA synthesis. Our results using a sensitive radiometric
assay indicate that abnormal HA production is associated
with about two thirds of Wilms' tumours; the precise nature
of this phenomenon at the cellular level is still to be
investigated.
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